OPTIMAL ORAL ANTICOAGULANT-THERAPY IN PATIENTS WITH MECHANICAL HEART-VALVES

被引:727
作者
CANNEGIETER, SC
ROSENDAAL, FR
WINTZEN, AR
VANDERMEER, FJM
VANDENBROUCKE, JP
BRIET, E
机构
[1] UNIV LEIDEN HOSP,DEPT CLIN EPIDEMIOL,2300 RC LEIDEN,NETHERLANDS
[2] UNIV LEIDEN HOSP,DEPT NEUROL,2300 RC LEIDEN,NETHERLANDS
[3] LEIDEN ANTICOAGULAT CLIN,LEIDEN,NETHERLANDS
关键词
D O I
10.1056/NEJM199507063330103
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. The optimal intensity of oral anticoagulant therapy for patients with mechanical heart valves (i.e., the level at which thromboembolic complications are effectively prevented without excessive bleeding) is not known. We attempted to determine the optimal intensity by calculating the incidence of both complications at different levels of anticoagulation. Methods. Data were collected on all patients with mechanical heart valves who have been seen at four regional Dutch anticoagulation clinics since 1985. The primary outcome events were episodes of thromboembolism or major bleeding, The intensity-specific incidence of each type of event was calculated as the number of events that occurred at a certain intensity of anticoagulation (expressed in terms of the international normalized ratio [INR]) divided by the number of patient-years during which the INR was at this level in the total patient population. Results. A total of 1608 patients were followed during 6475 patient-years. Cerebral embolism occurred in 43 patients (0.68 per 100 patient-years) and peripheral en embolism in 2 (0.03 per 100 patient-years). Intracranial and spinal bleeding occurred in 36 patients (0.57 per 100 patient-years) and major extracranial bleeding in 128 (2.1 per 100 patient-years). The optimal intensity of anticoagulation, at which the incidence of both complications was lowest, was achieved when the INR was between 2.5 and 4.9. Conclusions. The intensity of anticoagulant therapy for patients with prosthetic heart valves is optimal when the INR is between 2.5 and 4.9. To achieve this level of anticoagulation, a target INR of 3.0 to 4.0 is recommended.
引用
收藏
页码:11 / 17
页数:7
相关论文
共 20 条
[1]  
ALTMAN R, 1991, J THORAC CARDIOV SUR, V101, P427
[2]   THROMBOEMBOLIC AND BLEEDING COMPLICATIONS IN PATIENTS WITH MECHANICAL HEART-VALVE PROSTHESES [J].
CANNEGIETER, SC ;
ROSENDAAL, FR ;
BRIET, E .
CIRCULATION, 1994, 89 (02) :635-641
[3]   HEMATOLOGICAL COMPLICATIONS WITH THE ST-JUDE-VALVE AND REDUCED-DOSE COUMADIN [J].
DISESA, VJ ;
COLLINS, JJ ;
COHN, LH .
ANNALS OF THORACIC SURGERY, 1989, 48 (02) :280-283
[5]   RISK-FACTORS FOR COMPLICATIONS OF CHRONIC ANTICOAGULATION - A MULTICENTER STUDY [J].
FIHN, SD ;
MCDONELL, M ;
MARTIN, D ;
HENIKOFF, J ;
VERMES, D ;
KENT, D ;
WHITE, RH .
ANNALS OF INTERNAL MEDICINE, 1993, 118 (07) :511-520
[6]   ORAL ANTICOAGULANTS - MECHANISM OF ACTION, CLINICAL EFFECTIVENESS, AND OPTIMAL THERAPEUTIC RANGE [J].
HIRSH, J ;
DALEN, JE ;
DEYKIN, D ;
POLLER, L .
CHEST, 1992, 102 (04) :S312-S326
[7]   RISK-FACTORS FAR INTRACRANIAL HEMORRHAGE IN OUTPATIENTS TAKING WARFARIN [J].
HYLEK, EM ;
SINGER, DE .
ANNALS OF INTERNAL MEDICINE, 1994, 120 (11) :897-902
[8]   A MODEL FOR PLANNING OPTIMAL FOLLOW-UP FOR OUTPATIENTS ON WARFARIN ANTICOAGULATION [J].
KENT, DL ;
VERMES, D ;
MCDONELL, M ;
HENIKOFF, J ;
FIHN, SD .
MEDICAL DECISION MAKING, 1992, 12 (02) :132-141
[9]   JUDE,ST PROSTHESIS FOR AORTIC AND MITRAL-VALVE REPLACEMENT - A 10-YEAR EXPERIENCE [J].
KRATZ, JM ;
CRAWFORD, FA ;
SADE, RM ;
CRUMBLEY, AJ ;
STROUD, MR ;
AROM, KV .
ANNALS OF THORACIC SURGERY, 1993, 56 (03) :462-468
[10]   10-YEAR RESULTS WITH THE ST-JUDE MEDICAL PROSTHESIS [J].
NAIR, CK ;
MOHIUDDIN, SM ;
HILLEMAN, DE ;
SCHULTZ, R ;
BAILEY, RT ;
COOK, CT ;
SKETCH, MH .
AMERICAN JOURNAL OF CARDIOLOGY, 1990, 65 (03) :217-225